BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 235 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.62 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $869,268 | -27.2% | 122,778 | -27.6% | 0.00% | -40.0% |
| Q2 2023 | $1,194,603 | +119.4% | 169,688 | +159.9% | 0.01% | +66.7% |
| Q1 2023 | $544,551 | -100.0% | 65,294 | -44.4% | 0.00% | -81.2% |
| Q1 2022 | $1,910,631,000 | +77.1% | 117,505 | +50.8% | 0.02% | +100.0% |
| Q4 2021 | $1,078,915,000 | +217423.2% | 77,900 | +100.2% | 0.01% | +60.0% |
| Q2 2014 | $496,000 | – | 38,904 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Burrage Capital Management LLC | 864,916 | $13,674,000 | 13.71% |
| Sarissa Capital Management LP | 4,261,000 | $67,366,000 | 5.36% |
| ORACLE INVESTMENT MANAGEMENT INC | 1,920,733 | $30,367,000 | 4.18% |
| HealthCor Management, L.P. | 3,248,100 | $51,352,000 | 2.05% |
| Parkman Healthcare Partners LLC | 351,961 | $5,565,000 | 1.22% |
| Bain Capital Public Equity Management II, LLC | 1,560,730 | $24,675,000 | 1.06% |
| Baker Brothers Advisors | 12,710,818 | $200,958,000 | 0.88% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,835,000 | $44,821,000 | 0.80% |
| Biondo Investment Advisors, LLC | 265,840 | $4,203,000 | 0.72% |
| EAM Global Investors LLC | 157,065 | $2,483,000 | 0.69% |